• News & Media
  • Contact
  • Home
  • About Us
    • Our Commitment
    • The Story Behind Our Name
    • Leadership
    • Board of Directors
    • Grants & Funding
    • Investigator Sponsored Studies
  • Our Approach
    • Precision Medicines
    • Overcoming Resistance
    • Novel Biomarkers
  • Pipeline
    • Ziftomenib
    • Tipifarnib
    • KO-2806
    • Posters and Presentations
    • Scientific Manuscripts
    • Access To Investigational Drugs Outside a Clinical Study
  • Clinical Trials
    • Overview of Clinical Trials
    • Ziftomenib Clinical Trials
    • KOMET-001 – AML
    • KOMET-007 – AML
    • KOMET-008 – AML
    • Tipifarnib Clinical Trials
    • KURRENT-HN – HNSCC
    • KO-2806 Clinical Trials
    • FIT-001 – Solid Tumors
  • Patients & Caregivers
    • Acute Leukemias
    • Head & Neck Cancer
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • FAQs
    • Contact
  • Careers
    • Values
    • Life At Kura
    • Benefits
    • Open Positions
  • News & Media
  • Contact
  • Menu Menu

COO Kathy Ford on What Makes Kura a Top Workplace

December 2, 2021/in 2021, Life at Kura, Perspectives, Type
Read more
https://kuraoncology.com/wp-content/uploads/Top-Workplace-img-1.jpg 456 836 David Anderson /wp-content/uploads/kura-logo-registered-blue.svg David Anderson2021-12-02 08:00:282023-08-23 14:39:18COO Kathy Ford on What Makes Kura a Top Workplace

SDUT San Diego Top Workplaces 2021

November 21, 2021/in 2021, Awards, Perspectives, Type, Year
Read more
https://kuraoncology.com/wp-content/uploads/SDUT-2021.png 456 836 David Anderson /wp-content/uploads/kura-logo-registered-blue.svg David Anderson2021-11-21 08:00:232023-08-24 12:15:40SDUT San Diego Top Workplaces 2021

FDA’s Renewed Focus on Oncology Dosing Spooks Investors, but Companies Say They’re Ready

June 28, 2021/in 2021, Media Coverage, Perspectives, Type, Year
Read more
https://kuraoncology.com/wp-content/uploads/Dosing-Spooks-Investors-img.jpg 456 836 David Anderson /wp-content/uploads/kura-logo-registered-blue.svg David Anderson2021-06-28 08:00:312023-08-23 14:41:03FDA’s Renewed Focus on Oncology Dosing Spooks Investors, but Companies Say They’re Ready

Tipifarnib Demonstrates Encouraging Efficacy in Patients with Recurrent and/or Metastatic HNSCC with HRAS Mutations

April 21, 2021/in 2021, Media Coverage, Perspectives, Type, Year
Read more
https://kuraoncology.com/wp-content/uploads/AdobeStock_207889815-scaled.jpg 1709 2560 eallison /wp-content/uploads/kura-logo-registered-blue.svg eallison2021-04-21 08:00:332023-08-24 12:25:59Tipifarnib Demonstrates Encouraging Efficacy in Patients with Recurrent and/or Metastatic HNSCC with HRAS Mutations

CEO Troy Wilson on Sailing Through the Storm: Lessons from the Pandemic

March 26, 2021/in 2021, Kura Kommentary, Perspectives, Type, Year
Read more
https://kuraoncology.com/wp-content/uploads/Sailing-Through-the-Storm-img.jpg 456 836 David Anderson /wp-content/uploads/kura-logo-registered-blue.svg David Anderson2021-03-26 08:00:572023-08-23 14:40:01CEO Troy Wilson on Sailing Through the Storm: Lessons from the Pandemic

PharmaVoice 100: Innovator’s Journey

January 1, 2021/in 2021, Awards, Perspectives, Type, Year
Read more
https://kuraoncology.com/wp-content/uploads/PV-100_Troy-2021.png 456 836 David Anderson /wp-content/uploads/kura-logo-registered-blue.svg David Anderson2021-01-01 08:00:352023-08-24 12:23:23PharmaVoice 100: Innovator’s Journey
  • About Us
  • Our Commitment
  • The Story Behind Our Name
  • Leadership
  • Board of Directors
  • Grants & Funding
  • Investigator Sponsored Studies
  • Our Approach
  • Precision Medicines
  • Overcoming Resistance
  • Novel Biomarkers
  • Pipeline
  • Ziftomenib
  • Tipifarnib
  • KO-2806
  • Posters and Presentations
  • Scientific Manuscripts
  • Access to Investigational Drugs Outside a Clinical Study
  • Clinical Trials
  • Overview of Clinical Trials
  • Ziftomenib Clinical Trials
  • KOMET-001 – AML
  • KOMET-007 – AML
  • KOMET-008 – AML
  • Tipifarnib Clinical Trials
  • KURRENT-HN – HNSCC
  • KO-2806 Clinical Trials
  • FIT-001 – Solid Tumors
  • Patients & Caregivers
  • Acute Leukemias
  • Head & Neck Cancer
  • Investors
  • Overview
  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Financial Information
  • Analyst Coverage
  • FAQs
  • Contact
  • Careers
  • Values
  • Life at Kura
  • Benefits
  • Open Positions
  • News & Media
  • Press Releases
  • News & Perspectives
  • Expert Perspectives
  • Media Resources
  • Contact

Kura Oncology, Inc.
12730 High Bluff Drive, Suite 400
San Diego, CA 92130
(858) 500-8800

Kura Oncology, Inc.
2 Seaport Lane, Suite 8A
Boston, MA 02210
(617) 588-3755

Kura Oncology, Inc.
5510 Morehouse Drive, Suite 110
San Diego, California 92121

© 2025 Kura Oncology, Inc. All Rights Reserved | Terms of Use | Privacy Policy

Scroll to top Scroll to top Scroll to top